Senetek PLC Announces Positive Results From Pyratine-6(TM) Clinical Trial In Patients With Acne Rosacea

Senetek PLC (OTC Bulletin
Board: SNKTY), a Life Sciences company engaged in the development of
technologies that target the science of healthy aging, announced
positive study results from a clinical trial of Pyratine-6(TM) in patients
with acne rosacea. The findings have been accepted for presentation at the
International Investigative Congress of Dermatology at its May 2008 meeting
in Kyoto, Japan.


Based on positive results demonstrated in previous studies of
Pyratine-6(TM) (0.1%), for the remediation of photodamaged skin and
erythema which included unprecedented reduction in facial redness, in as
early as two weeks, an additional study was initiated for acne rosacea. The
follow up study was designed to extend these significant clinical findings
by assessing the effects of Pyratine-6(TM) (0.125%) in improving clinical
signs and symptoms of acne rosacea. Twenty-four subjects with
mild-to-moderate acne rosacea participated in the 12 week study. Subjects
were evaluated at baseline, 4, 8 and 12 weeks. Evaluations included
physician assessments of inflammatory lesion count, severity of erythema
and telangiectasia, and overall clinical improvement. Patient assessments
of signs and symptoms of rosacea and skin tolerance were also rated at each
follow-up. In addition, transepidermal water loss measurements and facial
photography were conducted at each visit.



Pyratine-6(TM) produced a progressive decrease in the symptoms
associated with rosacea including redness and acne lesions. All subject
self-assessments showed good tolerability and cosmetic acceptability. After
12 weeks there was overall clinical improvement in 80% of subjects,
including reduction of erythema and papules. Transepidermal water loss
measurements showed a 22% decrease in water loss, which supports an
improvement in skin barrier function. In view of the promising results, the
current study has been extended to 48 weeks.



Rosacea is a common chronic facial dermatosis, affecting 14 million
Americans, that is characterized by persistent erythema, telangiectasia,
papules and pustules. Patients with rosacea are often unable to tolerate
extended treatment periods with topical agents as a result of skin
sensitivity that accompanies rosacea. Due to the chronic nature of rosacea,
there is a continuing need for efficacious treatments that provide
sustained relief of its principal signs and symptoms.



Dr. Arisa Ortiz from the University of California Irvine, who is
presenting the results of this study at the 2008 International
Investigative Dermatology meeting in Kyoto, Japan, stated, "All study
subjects reported good tolerability and cosmetic acceptability to
Pyratine-6 (TM). The majority of subjects showed reductions in erythema,
papules, burning, stinging, and dryness, all of which are signs and
symptoms associated with acne rosacea. Transepidermal water loss
measurements showed a decrease in water loss which supports an improvement
in skin barrier function, attesting to the moisturizing properties of this
compound."
















Commenting on these findings, Frank Massino, Senetek Chairman and Chief
Executive Officer stated, "We are pleased by the positive study findings as
this further confirms the excellent safety and effectiveness profile of
Pyratine-6(TM). Response to Pyratine-6(TM) in the U.S. physician market has
been outstanding and we look forward to expanding our sales and marketing
efforts to accommodate increasing demand for this important product."



About Senetek PLC



Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the
development of breakthrough technologies that target the science of healthy
aging. The Company's extensive research collaborations have resulted in a
strong pipeline of patented compounds and products with broad therapeutic
applications and a leading presence in dermatology. Senetek collaborates
with established specialty pharmaceutical companies in the final
development and marketing of its proprietary products, most recently
resulting in the development of the best-selling anti-aging product sold in
the North American physician market.



For more information, visit the company's website at
senetekplc.



This news release contains statements that may be considered
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act. Forward-looking statements by their nature involve
substantial uncertainty, and actual results may differ materially from
those that might be suggested by such statements. Important factors
identified by the Company that it believes could result in such material
differences are described in the Company's Annual Report on Form 10-K for
the year 2007. However, the Company necessarily can give no assurance that
it has identified or will identify all of the factors that may result in
any particular forward-looking statement materially differing from actual
results, and the Company assumes no obligation to correct or update any
forward-looking statements which may prove to be inaccurate, whether as a
result of new information, future events or otherwise.


Senetek, PLC

senetekplc